Tyson Bio HT100-A Blood Glucose Monitoring System; Tyson Bio HT100-C Blood Glucose Monitoring System
K182047 · Tyson Bioresearch, Inc. · NBW · Nov 29, 2018 · Clinical Chemistry
Device Facts
Record ID
K182047
Device Name
Tyson Bio HT100-A Blood Glucose Monitoring System; Tyson Bio HT100-C Blood Glucose Monitoring System
Applicant
Tyson Bioresearch, Inc.
Product Code
NBW · Clinical Chemistry
Decision Date
Nov 29, 2018
Decision
SESE
Submission Type
Special
Regulation
21 CFR 862.1345
Device Class
Class 2
Attributes
Pediatric
Intended Use
Tysons Bio HT100-A Blood Glucose Monitoring System and Tyson Bio HT 100-C Blood Glucose Monitoring System are intended for single patient use.
Device Story
System uses electrochemical biosensor technology with glucose dehydrogenase (FAD) to measure glucose in capillary blood samples (0.7uL). Meter accepts Tyson Bio 50H test strips; performs amperometric detection. HT100-A includes voice feature; HT100-C includes voice and Bluetooth connectivity. Used by patients at home for self-monitoring. Patients apply blood to strip; meter displays quantitative glucose result. Output aids in diabetes management decisions. Devices feature auto-coding, 500-result memory, and alarm settings.
Clinical Evidence
No clinical data. Bench testing only; disinfection efficacy studies confirmed inactivation of HBV using Clorox Germicidal Wipes; robustness testing confirmed no performance degradation after 550 cleaning/disinfection cycles.
Technological Characteristics
Electrochemical biosensor; FAD-glucose dehydrogenase enzyme; amperometric detection. Dimensions: 106 x 66 x 20 mm. Power: 2 AAA batteries. Connectivity: Bluetooth (HT100-C only). Features: Auto-coding, voice output, 500-result memory. Operating range: 10-40°C, 10-90% humidity.
Indications for Use
Indicated for single patient use for blood glucose monitoring.
Regulatory Classification
Identification
A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.
Special Controls
*Classification.* Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
Predicate Devices
Tyson Bio HT100 Blood Glucose Monitoring System (k170079)
Tyson Bio HT100-B Blood Glucose Monitoring System (k170079)
Related Devices
K170079 — Tyson Bio HT100 Blood Glucose Monitoring System, Tyson Bio HT100-B Blood Glucose Monitoring System · Tyson Bioresearch, Inc. · Oct 6, 2017
K182046 — Tyson Bio HS100 Blood Glucose Monitoring System, Tyson Bio HS100-B Blood Glucose Monitoring System · Tyson Bioresearch, Inc. · Nov 30, 2018
K173505 — FORA GTel Blood Glucose Monitoring System · Foracare, Inc. · Aug 9, 2018
Submission Summary (Full Text)
{0}
SPECIAL 510(K): DEVICE MODIFICATION OIR DECISION SUMMARY
510(k) Number: k182047
This 510(k) submission contains information/data on modifications made to the applicant’s own class II or class I devices requiring 510(k). The following items are present and acceptable:
The name and 510(k) number of the applicant’s previously cleared device.
Tysons Bio HT100 Blood Glucose Monitoring System, Tyson Bio HT 100-B Blood Glucose Monitoring System (k170079)
1. Applicant’s statement that the INDICATION/INTENDED USE of the modified device as described in its labeling HAS NOT CHANGED along with the proposed labeling which includes instructions for use, package labeling, and, if available, advertisements or promotional materials (labeling changes are permitted as long as they do not affect the intended use).
2. A description of the device MODIFICATION(S), including clearly labeled diagrams, engineering drawings, photographs, user’s and/or service manuals in sufficient detail to demonstrate that the FUNDAMENTAL SCIENTIFIC TECHNOLOGY of the modified device has not changed.
This change was for:
The Tyson Bio HT100 Blood Glucose Monitoring System was modified as follows to create the Tyson Bio HT100-A Blood Glucose Monitoring System:
- Addition of Voice Guidance Feature
- Change in meter color from pale grey to white.
- Change in system name from Tyson Bio HT100 Blood Glucose Monitoring System to create Tyson Bio HT100-A Blood Glucose Monitoring system
The Tyson Bio HT100-B Blood Glucose Monitoring System was modified as follows to create the Tyson Bio HT100-C Blood Glucose Monitoring System:
- Addition of Voice Guidance Feature
- Change in meter color from pale grey to white.
- Change in system name from Tyson Bio HT100-B Blood Glucose Monitoring System to create Tyson Bio HT100-C Blood Glucose Monitoring system
3. Comparison Information (similarities and differences) to applicant’s legally marketed predicate device including, labeling, intended use, physical characteristics, and specifications.
{1}
4. A Design Control Activities Summary which includes:
a) Identification of Risk Analysis method(s) used to assess the impact of the modification on the device and its components, and the results of the analysis
b) Based on the Risk Analysis, an identification of the verification and/or validation activities required, including methods or tests used and acceptance criteria to be applied
The labeling for this modified subject device has been reviewed to verify that the indication/intended use for the device is unaffected by the modification. In addition, the applicant’s description of the particular modification(s) and the comparative information between the modified and unmodified devices demonstrate that the fundamental scientific technology has not changed. The applicant has provided the design control information as specified in The New 510(k) Paradigm and on this basis, I recommend the device be determined substantially equivalent to the previously cleared (or their preamendment) device.
Tysons Bio HT100-A Blood Glucose Monitoring System and Tyson Bio HT 100-C Blood Glucose Monitoring System are intended for single patient use. Disinfection efficacy studies were performed on the exterior materials comprising the meter demonstrating complete inactivation of hepatitis B Virus (HBV) with Clorox Germicidal Wipe (EPA Reg. No: 67619-12). The sponsor also conducted robustness studies and demonstrated that there was no change in performance or in the external materials of the meter after 550 cleaning and disinfection cycles representing 5 years of single patient use. Labeling was reviewed for adequate instructions for the validated cleaning and disinfection procedures and found to be acceptable
2
Panel 1
/
Sort by
Ready
Predicate graph will load when search results are available.
Embedding visualization will load when search results are available.
PDF viewer will load when search results are available.
Loading panels...
Select an item from Submissions
Click any panel, subpart, regulation, product code, or device to see details here.
Section Matches
Results will appear here.
Product Code Matches
Results will appear here.
Special Control Matches
Results will appear here.
Loading collections...
Loading
My Alerts
You will receive email notifications based on the filters and frequency you set for each alert.
Sort by:
Create Alert
Search Filters
Agent Token
Create a read-only bearer token for Claude, ChatGPT, or other agents that can call HTTP APIs.